Please assess the completion status of the following clinical trial:

Trial Title: A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with diagnosis of Type 2 Diabetes Mellitus, treated with diet and exercise or a stable dose of 1 OAD at screening~* Body mass index (BMI) 17 to 40 kg/ m\^2 inclusive~* Subjects who are OAD naïve, HbA1c between 7.0% and 10.0% at Screening and at Visit 2; for subjects who enter the study with 1 OAD, HbA1c between 6.5% and 9.5% at Screening and HbA1c between 7.0% and 10.0% at Visit 2~* Creatinine clearance \>30 mL/min (calculated using the Cockcroft-Gault formula)~Exclusion Criteria:~* History of type 1 diabetes mellitus •Female subject is pregnant, lactating, or \<6 weeks postpartum•~* Clinically significant cardiovascular and/or cerebrovascular disease~* Current ongoing symptomatic biliary disease, clinical signs or symptoms of pancreatitis, or a history of chronic or acute pancreatitis, as determined by the investigator~* Serum amylase \>=3 ×ULN and/or serum lipase \>=2 × ULN and/or subject is experiencing any symptoms possibly related to pancreatitis~* Prior use of a TZD or GLP-1R agonist within 4 months before Screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Albiglutide 30 mg weekly (Type: EXPERIMENTAL): Subjects will be randomly assigned to double blind albiglutide 30 mg weekly treatment for 52 weeks
- Albiglutide 50 mg weekly (Type: EXPERIMENTAL): Subjects will be randomly assigned to double blind albiglutide 50 mg weekly until Week 52
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will be randomly assigned to double blind matching albiglutide placebo administered weekly. Subjects will then cross-over to double-blind treatment with albiglutide 30 mg weekly at Week 24 until Week 52
- Liraglutide 0.9 mg daily (Type: ACTIVE_COMPARATOR): Subjects will be randomly assigned to open-label liraglutide for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).